A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS)

Status
Active
Cancer Type
Leukemia
Trial Phase
Eligibility
18 and over, Female
Study Type
Natural history/Epidemiology
NCD ID
NCT01289054
Protocol IDs
CSTI571A2403 (primary)
Study Sponsor
Novartis Pharmaceuticals Corporation

Summary

This is a voluntary, international, primarily prospective, observational, exposure-registration and follow-up study of women receiving Imatinib and/or Nilotinib during pregnancy or within six months prior to pregnancy.